Last reviewed · How we verify
halobetasol
At a glance
| Generic name | halobetasol |
|---|---|
| Sponsor | Azidus Brasil |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Duobrii Treatment of Acne Keloidalis Nuchae (AKN) (PHASE3)
- Investigator Initiated Trial to Study Duobrii® Lotion in the Treatment of Mild Plaque Psoriasis in Adults (PHASE3)
- A Demonstration of the Hair and Scalp Benefits of Duobrii in Scalp Psoriasis (PHASE4)
- Anti-Inflammatory Effects of 0.045% Tazarotene/0.01% Halobetasol Lotion in Psoriasis (PHASE4)
- Combination of Halobetasol Propionate and Tazarotene Lotion (Duobrii®) for Palmoplantar Plaque Type Psoriasis (PHASE4)
- Safety and Efficacy of CITI-002 in Adult Patients With Moderate Grade Hemorrhoids (PHASE2)
- Comparison Of Efficacy Of Tazarotene 0.045% Vs Halobetasol Propionate 0.01% Lotion For Treatment of Scalp Psoriasis (NA)
- Adrenal Suppression and Absorption Study of Halobetasol Propionate Foam in Subjects 12-17 With Plaque Psoriasis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- halobetasol CI brief — competitive landscape report
- halobetasol updates RSS · CI watch RSS
- Azidus Brasil portfolio CI